Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00721591 · ClinicalTrials.gov registry record
Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 14
- Enrollment target
NCT00721591: Completed study, sponsored by University of Chicago.
NCT00721591 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00721591 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
To determine, through pharmacokinetic parameters, the ideal dosing protocol for dalteparin (a low molecular weight heparin) and unfractionated heparin for women desiring pregnancy who have evidence of an acquired (specifically, antiphospholipid syndrome) or inherited thrombophilia.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-03 |
| Est. Completion | 2014-07 |
What the finished NCT00721591 record still lists
NCT00721591 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00721591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00721591 about?
NCT00721591 is a clinical study titled "Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy". To determine, through pharmacokinetic parameters, the ideal dosing protocol for dalteparin (a low molecular weight heparin) and unfractionated heparin for women desiring pregnancy who have evidence of an acquired (specifically, antiphospholipid syndrome) or inherited thrombophilia.
What is the current status of trial NCT00721591?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2005-03. Estimated completion is 2014-07.
Who is sponsoring clinical trial NCT00721591?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia